The Safety and Tolerability of GT0918 in Subjects With mHSPC and mCRPC
Condition(s):Metastatic Castrate Resistant Prostate Cancer (mCRPC); Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)Last Updated:February 12, 2024Completed
Hide Studies Not Open or Pending
Condition(s):Metastatic Castrate Resistant Prostate Cancer (mCRPC); Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)Last Updated:February 12, 2024Completed
Condition(s):Prostate CancerLast Updated:March 11, 2020Completed
Condition(s):Prostate CancerLast Updated:November 29, 2018Completed
Condition(s):Hormone-refractory Prostate CancerLast Updated:March 5, 2015Completed
Condition(s):Adenocarcinoma of the Prostate; Recurrent Prostate Cancer; Stage I Prostate Cancer; Stage IIA Prostate Cancer; Stage IIB Prostate Cancer; Stage III Prostate CancerLast Updated:January 5, 2021Completed
Condition(s):Castration Levels of Testosterone; Castration-Resistant Prostate Carcinoma; Castration-Resistant Prostate Carcinoma Refractory to Second-Generation Androgen Receptor Axis-Targeted Agents; Metastatic Prostate Adenocarcinoma; Progressive Disease; Prostate Carcinoma Metastatic in the Bone; Prostate Carcinoma Metastatic in the Soft Tissue; PSA Progression; Stage IVB Prostate Cancer AJCC v8; Testosterone Less Than 50 ng/dLLast Updated:April 27, 2022Active, not recruiting
Condition(s):Prostate CancerLast Updated:December 16, 2021Completed
Condition(s):Prostate CancerLast Updated:October 31, 2012Terminated
Condition(s):Hormone Sensitive Metastatic Prostate Cancer; DNA Damage Repair Deficiency; Chemotherapy Effect; Chemotherapeutic ToxicityLast Updated:October 24, 2022Recruiting
Condition(s):Prostate CancerLast Updated:March 24, 2021Completed
At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.